Table 2.
Effects of OLE and HT on PBMC viability and on normalized number assayed on cells from donors of the Adult and Senior groups.
| Adult (n = 4) | Senior (n = 4) | Student’s t-Test | ||
|---|---|---|---|---|
| Percentage of live cells | ||||
| Untreated | 86.25 ± 3.59 | 86 ± 3.65 | n.s. | |
| ETOH | 87 ± 6.06 | 88.5 ± 7.05 | n.s. | |
| LPS | 90 ± 8.12 | 77.5 ± 14.2 | n.s. | |
| OLE1 | 83.75 ± 4.86 | 84.75 ± 1.89 | n.s. | |
| OLE1 + LPS | 86.5 ± 6.56 | 90.75 ± 1.71 | n.s. | |
| OLE5 | 81.75 ± 4.19 | 83 ± 6.98 | n.s. | |
| OLE5 + LPS | 77 ± 13.44 | 83.75 ± 3.69 | n.s. | |
| OLE10 | 82.5 ± 7.19 | 82.5 ± 5.07 | n.s. | |
| OLE10 + LPS | 81.5 ± 6.76 | 84 ± 6.68 | n.s. | |
| HT1 | 90.75 ± 3.78 | 77.5 ± 9.47 | 0.041 | |
| HT1 + LPS | 78.25 ± 6.24 | 76.5 ± 10.72 | n.s. | |
| HT5 | 78.25 ± 6.4 | 76.25 ± 20.27 | n.s. | |
| HT5 + LPS | 87.5 ± 9.68 | 81.5 ± 10.15 | n.s. | |
| HT10 | 83.25 ± 7.27 | 78 ± 8.04 | n.s. | |
| HT10 + LPS | 78.5 ± 11.71 | 76.75 ± 7.85 | n.s. | |
| Repeated measures ANOVA | n.s. | n.s. | ||
| Normalized cell number | ||||
| ETOH | 1.04 ± 0.27 | 1.06 ± 0.37 | n.s. | |
| LPS | 0.85 ± 0.31 | 0.77 ± 0.51 | n.s. | |
| OLE1 | 0.97 ± 0.24 | 0.66 ± 0.41 | n.s. | |
| OLE1 + LPS | 0.92 ± 0.48 | 0.98 ± 0.54 | n.s. | |
| OLE5 | 0.77 ± 0.16 | 1.08 ± 0.46 | n.s. | |
| OLE5 + LPS | 1.21 ± 0.37 | 1.13 ± 0.79 | n.s. | |
| OLE10 | 1.09 ± 0.39 | 0.9 ± 0.23 | n.s. | |
| OLE10 + LPS | 1.06 ± 0.16 | 0.85 ± 0.51 | n.s. | |
| HT1 | 1.12 ± 0.65 | 1.04 ± 0.73 | n.s. | |
| HT1 + LPS | 1.04 ± 0.29 | 1.26 ± 0.58 | n.s. | |
| HT5 | 0.96 ± 0.24 | 1.39 ± 0.89 | n.s. | |
| HT5 + LPS | 1.26 ± 0.42 | 1 ± 0.61 | n.s. | |
| HT10 | 1.35 ± 0.4 | 1.04 ± 0.28 | n.s. | |
| HT10 + LPS | 1.08 ± 0.6 | 1.3 ± 0.7 | n.s. | |
| Repeated measures ANOVA | n.s. | n.s. |
Results are expressed as mean ± standard deviation. Statistical analysis is discussed in detail in the text. n, number of subjects; Untreated, cells that received no treatment; ETOH, cells treated only with vehicle (ethanol); LPS, cells treated with 1 μg/mL lipopolysaccharide; OLE1, cells treated with 1 μM oleuropein; OLE1 + LPS, cells pre-treated with 1 μM oleuropein, then incubated with 1 μg/mL LPS; OLE5, cells treated with 5 μM oleuropein; OLE5 + LPS, cells pre-treated with 5 μM oleuropein, then incubated with 1 μg/mL LPS; OLE10, cells treated with 10 μM oleuropein; OLE10 + LPS, cells pre-treated with 10 μM oleuropein, then incubated with 1 μg/mL LPS; HT1, cells treated with 1 μM hydroxytyrosol; HT1 + LPS, cells pre-treated with 1 μM hydroxytyrosol, then incubated with 1 μg/mL LPS; HT5, cells treated with 5 μM hydroxytyrosol; HT5 + LPS, cells pre-treated with 5 μM hydroxytyrosol, then incubated with 1 μg/mL LPS; HT10, cells treated with 10 μM hydroxytyrosol; HT10 + LPS, cells pre-treated with 10 μM hydroxytyrosol, then incubated with 1 μg/mL LPS; n.s., non-significant.